Clinical Trial Update: In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol® [Phase 2]

View source ↗

Summary

Phase 2 trial updating autologous therapeutic vaccination against solid cancers using intratumoral Hiltonol shows completed status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Melanoma

Drugs mentioned

• Hiltonol (Poly-ICLC)

Snippet

Sponsor: Oncovir, Inc. | Conditions: Melanoma, Head and Neck Cancer | Phase 2 | Status: COMPLETED